Search results
Results from the WOW.Com Content Network
Serotonin plays an important role in numerous physiological conditions. 5-HT 2 receptor antagonists have long been known, but recently 5-HT 2 receptor agonists are becoming promising agents in the development for new antipsychotic drugs. Historically, most pharmacological research on antipsychotic drugs have concentrated on the 5-HT 2A receptor ...
NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers. [1] NNC2215 can sense the glucose concentration presence in blood. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. [2]
Toggle Antipsychotics subsection. 1.1 Antipsychotic esters. 1.1.1 Typical antipsychotics. 1.1.2 Atypical antipsychotics. 2 See also. 3 References. 4 External links.
Semaglutide medications first hit the market to treat diabetes, but more recently, they’ve been used for weight loss. Semaglutide meds are part of a class of glucagon-like peptide-1 (GLP-1 ...
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. [3] [4] It is taken by mouth. [3] Side effects of pimavanserin include peripheral edema and confusion. [3]
Recently, the FDA required the manufacturers of some atypical antipsychotics to include a warning about the risk of hyperglycemia and Type II diabetes with atypical antipsychotics. Some evidence suggests that ziprasidone does not cause insulin resistance to the degree of other atypical antipsychotics, such as olanzapine. Weight gain is also ...